FDA Approves Drug With Digital Ingestion Tracking System

Share this content:
FDA Approves Drug With Digital Ingestion Tracking System
FDA Approves Drug With Digital Ingestion Tracking System

WEDNESDAY, Nov. 15, 2017 (HealthDay News) -- The first drug in the United States with a digital ingestion tracking system has been approved by the U.S. Food and Drug Administration.

Abilify MyCite consists of aripiprazole tablets with an embedded sensor in each that sends a message to a wearable patch when the medication been taken. This allows the patients to track medication ingestion via smartphone, and they can also permit their physicians and caregivers to access the information through a web-based portal.

Abilify MyCite hasn't been proven to improve patient compliance with a treatment regimen, the FDA said in a news release. And the drug should not be used in an attempt to track real-time ingestion since detection could be delayed, the agency added.

As with similar antipsychotic drugs, Abilify MyCite's label includes a boxed warning that elderly people with dementia-related psychosis have an increased mortality risk if they take the medication, the FDA said. The label also warns of increased risk of suicidal ideation among children, adolescents, and young adults.

Abilify MyCite's approval was granted to Japan's Otsuka Pharmaceuticals Co. The sensor technology and patch are made by Proteus Digital Health in Redwood City, California.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Deep Learning-Enhanced Device Detects Diabetic Retinopathy

Deep Learning-Enhanced Device Detects Diabetic Retinopathy

Device sensitivity/specificity 100/97.8 percent for vision-threatening diabetic retinopathy

Altered Gut Microbiome Seen in Patients With Active Lupus

Altered Gut Microbiome Seen in Patients With Active ...

Patients with lupus had fivefold greater representation of Ruminococcus gnavus

Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer

Combo Regimens Effective for Tx of Metastatic Renal ...

Two large trials show benefits for pembrolizumab-axitinib and avelumab-axitinib versus sunitinib

is free, fast, and customized just for you!




Already a member?

Sign In Now »